Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Lockheed Martin Corporation (LMT) Price & Performance

Cytokinetics IncTrade
Lockheed Martin CorporationTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Lockheed Martin Corporation — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Lockheed Martin Corporation trades at $607 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 13× Cytokinetics Inc's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKLMT
Market Cap
$10.63B$137.96B
Sector
TechnologyIndustrials
52-Week High
$87.26$676.70
52-Week Low
$34.31$431.56
Enterprise Value
$10.74B$154.71B
Dividend Yield
2.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.

The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.

Lockheed Martin Corporation

Lockheed Martin (LMT) trades at $606.71, up 0.59% on the day, near its consensus price target of $608. The stock shows bullish technical momentum with strong moving average signals and is supported by a record $230.4 billion backlog as of Q2 2026 (Seeking Alpha, August 4, 2026). Recent earnings beat expectations in Q2 2026 with EPS of $7.94 versus $7.22 estimated, though Q4 2025 and Q1 2026 results missed. The company maintains robust cash flow, with 2025 operating cash flow at $8.56 billion, and benefits from major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, August 11, 2026).

Outlook is positive due to strong defense spending trends and execution, but risks include earnings volatility and debt levels. The stock offers steady dividends and growth potential, with analyst consensus leaning bullish. Key risks involve reliance on government contracts and macroeconomic pressures on defense budgets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Lockheed Martin Corporation

Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.

Read more on LMT